Q/C Technologies, Inc.

NasdaqCM:QCLS Stock Report

Market Cap: US$30.2m

Q/C Technologies Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Q/C Technologies.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth14.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Sep 01

We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • May 19

We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 30

MyMD Pharma receives grant from European patent office for Supera-CBD compound

MyMD Pharma (NASDAQ:MYMD) said on Tuesday that it had received a grant from the European Patent Office for its application, under which the allowed claims cover its Supera-CBD, to treat pain and anxiety, compound as a new molecular entity and pharmaceutical formulations containing the compound. MYMD-1 is an oral selective inhibitor of tumor necrosis factor-alpha, that drives chronic inflammation, is being studied to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan. The upcoming patent grant adds to the company’s growing portfolio that includes patents in the US, Australia, Canada, Israel, and South Korea.
Seeking Alpha • Jul 08

Oramed, MyMD surge on plans for early-stage oral COVID vaccine data release in Q3

Oramed Pharmaceuticals' (NASDAQ:ORMP) Thursday announcement it will report Q1 data on its oral COVID-19 vaccine this quarter has boosted its shares as well as that of MyMD Pharmaceuticals (NASDAQ:MYMD). MyMD (MYMD) partially owns Oravax Medical, a subsidiary of Oramed (ORMP) that is developing the vaccine. In early afternoon trading, Oramed (ORMP) was up ~25% while MyMD added ~27%. Volume in both companies was also high. as of 1245p ET, ~3.2M Oramed (ORMP) shares had traded hands. Daily average volume is ~846K. For MyMD (MYMD), the figure was ~1.6M shares (daily average ~65.7K). Vaxart (VXRT) is also developing an oral vaccine pill.
Analysis Article • Apr 12

Companies Like MyMD Pharmaceuticals (NASDAQ:MYMD) Could Be Quite Risky

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 29

MyMD Pharmaceuticals (NASDAQ:MYMD) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Q/C Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:QCLS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2026N/A-15-12-10N/A
12/31/2025N/A-15-11-9N/A
9/30/2025N/A-12-10-8N/A
6/30/2025N/A-11-9-9N/A
3/31/2025N/A-18-10-10N/A
12/31/2024N/A-27-9-9N/A
9/30/2024N/A-29-9-9N/A
6/30/2024N/A-23-10-10N/A
3/31/2024N/A-18-11-11N/A
12/31/2023N/A-8-13-13N/A
9/30/2023N/A-7-13-13N/A
6/30/2023N/A-14-14-14N/A
3/31/2023N/A-13-14-14N/A
12/31/2022N/A-15-12-12N/A
9/30/2022N/A-15-15-15N/A
6/30/2022N/A-16-17-17N/A
3/31/2022N/A-31-20-20N/A
12/31/2021N/A-30-20-20N/A
9/30/2021N/A-31-16-16N/A
6/30/2021N/A-29-11-11N/A
3/31/2021N/A-12-5-5N/A
12/31/2020N/A-9-5-5N/A
12/31/2019N/A-10N/A-5N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if QCLS's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if QCLS's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if QCLS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if QCLS's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if QCLS's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if QCLS's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 07:58
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Q/C Technologies, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.